We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for iQIYI (IQ) This Earnings Season?
Read MoreHide Full Article
iQIYI (IQ - Free Report) is set to report second-quarter 2019 results on Aug 19.
In the last reported quarter, the company reported adjusted loss of 35 cents per share. The loss was narrower than the Zacks Consensus Estimate of a loss of 52 cents.
Revenues surged 43% from the year-ago quarter to RMB6.99 billion ($1 billion).
Total subscribers increased 57.9% year over year to 96.8 million in the first-quarter.
For the second quarter, management anticipates total revenues between RMB6.91 billion ($1 billion) and RMB7.29 billion ($1.1 billion).
The Zacks Consensus Estimate for revenues is currently pegged at $1.06 billion, indicating growth of 13.4% from the year-ago quarter’s reported figure.
The consensus mark for second-quarter earnings has been steady at a loss of 43 cents over the past seven days.
Let’s see how things are shaping up prior to this announcement.
Key Factors to Watch
iQIYI’s solid content slate is a key catalyst. The company released The Legend of White Snake and The Thunder in the to-be-reported quarter. Notably, The Thunder received an overwhelming response in China and AT&T’s (T - Free Report) HBO acquired the Southeast Asia licensing rights of the series.
Further, the company’s ability to bring exclusive and original content to its platform is likely to expand the subscriber base. The success of the original variety show The Big Band is noteworthy in this regard. Launched during the second quarter, this musical variety show featured 31 top Chinese bands.
Notably, iQIYI’s subscriber base surpassed 100 million in the to-be-reported quarter.
Moreover, partnerships with the likes of Microsoft (MSFT - Free Report) division LinkedIn, Viacom, Ctrip, AIS and China Unicom Global Limited are expected to boost user engagement.
Notably, LinkedIn became the first partner of iQIYI’s Knowledge App. The partnership was announced at the 2019 iQIYI World Conference. LinkedIn will exclusively provide rich video content on global and local professional learning, and interviews with global business key opinion leaders.
Additionally, iQIYI’s gaming business strengthened post its acquisition of Skymoons. The expanding gaming portfolio is expected to drive the top line in the second quarter.
However, the online advertising business is likely to be sluggish due to the unfavorable macroeconomic environment in China and slower-than-expected recovery of in-feed advertising.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. Stocks with a Zacks Rank #4 or 5 (Sell rated) are best avoided.
iQIYI has a Zacks Rank #3 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Momo (MOMO - Free Report) has an Earnings ESP of +2.04% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nutanix (NTNX - Free Report) has an Earnings ESP of +4.80% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
What's in the Cards for iQIYI (IQ) This Earnings Season?
iQIYI (IQ - Free Report) is set to report second-quarter 2019 results on Aug 19.
In the last reported quarter, the company reported adjusted loss of 35 cents per share. The loss was narrower than the Zacks Consensus Estimate of a loss of 52 cents.
Revenues surged 43% from the year-ago quarter to RMB6.99 billion ($1 billion).
Total subscribers increased 57.9% year over year to 96.8 million in the first-quarter.
For the second quarter, management anticipates total revenues between RMB6.91 billion ($1 billion) and RMB7.29 billion ($1.1 billion).
The Zacks Consensus Estimate for revenues is currently pegged at $1.06 billion, indicating growth of 13.4% from the year-ago quarter’s reported figure.
iQIYI, Inc. Sponsored ADR Price and EPS Surprise
iQIYI, Inc. Sponsored ADR price-eps-surprise | iQIYI, Inc. Sponsored ADR Quote
The consensus mark for second-quarter earnings has been steady at a loss of 43 cents over the past seven days.
Let’s see how things are shaping up prior to this announcement.
Key Factors to Watch
iQIYI’s solid content slate is a key catalyst. The company released The Legend of White Snake and The Thunder in the to-be-reported quarter. Notably, The Thunder received an overwhelming response in China and AT&T’s (T - Free Report) HBO acquired the Southeast Asia licensing rights of the series.
Further, the company’s ability to bring exclusive and original content to its platform is likely to expand the subscriber base. The success of the original variety show The Big Band is noteworthy in this regard. Launched during the second quarter, this musical variety show featured 31 top Chinese bands.
Notably, iQIYI’s subscriber base surpassed 100 million in the to-be-reported quarter.
Moreover, partnerships with the likes of Microsoft (MSFT - Free Report) division LinkedIn, Viacom, Ctrip, AIS and China Unicom Global Limited are expected to boost user engagement.
Notably, LinkedIn became the first partner of iQIYI’s Knowledge App. The partnership was announced at the 2019 iQIYI World Conference. LinkedIn will exclusively provide rich video content on global and local professional learning, and interviews with global business key opinion leaders.
Additionally, iQIYI’s gaming business strengthened post its acquisition of Skymoons. The expanding gaming portfolio is expected to drive the top line in the second quarter.
However, the online advertising business is likely to be sluggish due to the unfavorable macroeconomic environment in China and slower-than-expected recovery of in-feed advertising.
What Our Model Says
According to the Zacks model, a company with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) has a good chance of beating estimates if it also has a positive Earnings ESP. Stocks with a Zacks Rank #4 or 5 (Sell rated) are best avoided.
iQIYI has a Zacks Rank #3 and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Stocks to Consider
Here are some companies, which, per our model, have the right combination of elements to post an earnings beat this quarter:
Momo (MOMO - Free Report) has an Earnings ESP of +2.04% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Nutanix (NTNX - Free Report) has an Earnings ESP of +4.80% and a Zacks Rank #3.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>